[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620071":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":37,"collaborators":10,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":42,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":10,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"The Affiliated Hospital of Qingdao University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"exposed group",null,"subjects undergoing rapamycin-eluting stent implantation",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Yong Zhang","CONTACT","(+86) 18661818866","bravezhang@126.com",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":10,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Qingdao University Affiliated Hospital","RECRUITING","Qingdao","Shandong","China","CN",{"type":27,"coordinates":28},"Point",[29,30],120.38042,36.06488,{"lat":30,"lon":29},[33,35],{"name":14,"role":15,"phone":34,"phoneExt":10,"email":17},"18661818866",{"name":14,"role":36,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":36,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"zhangyong","Chief Physician, Department of Neurointerventional Medicine, The Affiliated Hospital of Qingdao University","100620071","rapamycin-eluting-vertebral-stents-in-the-real-world-treatment-of-symptomatic-intracranial-atherosclerotic-stenosis-100620071",false,"NCT07352852","Rapamycin-Eluting Vertebral Stents In The Real-World Treatment of Symptomatic Intracranial Atherosclerotic Stenosis","Rapamycin-eluting Vertebral Stents in the Real-world Treatment of Symptomatic Intracranial Atherosclerotic Stenosis","BRIDGE-INTRA","Inclusion Criteria:\n\n* Age ≥18 and ≤80 years;\n* Symptomatic intracranial atherosclerotic stenosis patients with ineffective medical treatment;\n* Digital subtraction angiography (DSA) shows target lesion stenosis ≥70%;\n* Suitable for implantation of rapamycin-targeted drug-eluting stents;\n* The patient and\u002For their authorized representative can understand the study purpose, agree to participate, and sign the informed consent form.\n\nExclusion Criteria:\n\n* Modified Rankin Scale (mRS) score ≥3;\n* Ischemic stroke within the past 2 weeks;\n* Presence of more than 2 intracranial atherosclerotic stenosis lesions requiring interventional treatment;\n* Severe contraindications to heparin, aspirin, ticagrelor, clopidogrel, or other antiplatelet drugs, and inability to tolerate anticoagulant\u002Fantiplatelet therapy;\n* Severe dysfunction of major organs (e.g., severe hepatic insufficiency, renal insufficiency, heart failure);\n* Severe allergies to contrast agents, rapamycin and its derivatives, cobalt-based alloys, or polylactic acid;\n* Pregnant or lactating women;\n* Participation in other drug or device studies without reaching the endpoint;\n* Life expectancy less than 12 months;\n* Lesions or vascular access deemed unsuitable for rapamycin drug-eluting stent implantation by the operator.","ALL","18 Years","80 Years",{"count":52,"type":53},300,"ESTIMATED","OBSERVATIONAL","This clinical trial is a prospective, multicenter, single-arm study. About 300 subjects undergoing rapamycin-eluting stent implantation will be enrolled based on the inclusion and exclusion criteria. The primary endpoint is the rate of any stroke or death within 1 month. Secondary efficacy endpoints include immediate stent implantation success. Safety endpoints cover the incidence of stroke or neurological death, target-vessel-related stroke or death, all-cause mortality, and mRS scores at 12-month follow-ups. Subjects will be clinically followed up before surgery, device implantation, discharge, and at 1, 6, and 12 months post-surgery. An imaging subgroup of at least 80 subjects who agree to DSA follow-up at 12 months will assess in-stent restenosis (\\>50%).",[57,58],"Intracranial Arterial Stenosis","Brain Diseases","2026-01-13",{"date":61,"type":62},"2026-01-20","ACTUAL",{"date":64,"type":62},"2025-05-14",{"date":66,"type":53},"2028-12-31",{"name":5,"class":6},1]